[Skip to Content]
[Skip to Content Landing]
Commentary
October 25, 1999

The Use of Sublingual Nifedipine: A Continuing Concern

Arch Intern Med. 1999;159(19):2259-2260. doi:10.1001/archinte.159.19.2259

IN 1995, the Cardiorenal Advisory Committee of the Food and Drug Administration, after a lengthy deliberation, unanimously decided that sublingual nifedipine should not officially be approved for the treatment of hypertensive emergencies. Despite this decision and despite authoritative voices1-4 warning against this practice, the use of short-acting nifedipine for what was perceived as hypertensive emergencies remained widespread in the United States and all over the globe.

×